Aflatoxin Treatment Project In Kenya Faces Challenge In Marketing Product To Poor Farmers

IRIN examines an 18-month project in Kenya testing a maize treatment aimed at controlling “a deadly fungus, aflatoxin,” which has the potential to cause cancer, immune system suppression, growth retardation, liver disease and death among the “literally billions of people in the developing world” who are chronically exposed to the fungus.

The news agency reports that “the project also needs to answer some key questions about how to market [the treatment] aflasafe,” because “[f]or farmers, the question of affordability and added value is central, and could determine whether or not they use the product, no matter how effective it is” (6/30).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.